期刊
TRANSLATIONAL ONCOLOGY
卷 12, 期 10, 页码 1375-1385出版社
ELSEVIER SCIENCE INC
DOI: 10.1016/j.tranon.2019.07.007
关键词
-
类别
资金
- Brain Tumour Research
- Ollie Young Foundation
- Foundation for Science and Technology (FCT), Portugal [IF/00614/2014]
- FCT exploratory grant [IF/00614/2014/CP12340006]
- FCT Research Center Grant [UID/BIM/04773/2013CBMR1334]
High-grade gliomas (HGGs) are aggressive primary brain tumors with local invasive growth and poor clinical prognosis in both adult and pediatric patients. Clinical response is compounded by resistance to standard frontline antineoplastic agents, an absence of novel therapeutics, and poor in vitro models to evaluate these. We screened a range of recently identified anticancer compounds in conventional adult, pediatric, and new biopsy-derived HGG models. These in vitro lines showed a range of sensitivity to standard chemotherapeutics, with varying expression levels of the prognostic markers hypoxia-induced factor (HIF) 1 alpha and p53. Our evaluation of lead DIVERSet library compounds identified that JAG-6A, a compound that was significantly more potent than temozolomide or etoposide, was effective against HGG models in two-dimensional and three-dimensional systems; mediated this response by the potent inhibition of topoisomerase Ii alpha; remained effective under normoxic and hypoxic conditions; and displayed limited toxicity to non-neoplastic astrocytes. These data suggest that JAG-6A could be an alternative topoisomerase II alpha inhibitor and used for the treatment of HGG.
作者
我是这篇论文的作者
点击您的名字以认领此论文并将其添加到您的个人资料中。
推荐
暂无数据